
Journal of Medicinal Chemistry p. 947 - 959 (1986)
Update date:2022-07-30
Topics:
Cherkez, S.
Herzig, J.
Yellin, H.
The synthesis of the isomeric series 6-chloro-7-sulfamoyl-and 7-chloro-6-sulfamoyl-1(2H)-phthalazinones (1 and 2) and 6-chloro-7-sulfamoyl- and 7-chloro-6-sulfamoyl-3,4-dihydro-1(2H)-phthalazinones (3 and 4), combining structural features characteristic to furosemide and hydralazine, is described, the mechanism of the formation of 1 and 2 is discussed, and their structure-activities relationships are studied.Preliminary screening in the rat shows that series 1 and 3 exhibit diuretic and saluretic activity similar to that of chlorothiazide with, however, Na+/K+ ratios more favorable than chlorothiazide and furosemide.The compounds of series 2 and 4 are practically inactive.All four series show initial antihypertensive activity lower than that of hydralazine.However, compounds 1a, 1c, and 4a show a higher activity at 8 and/ or 24 h after administration and thus may offer a unique combination of a "loop" diuresis with direct long-acting peripheral vasodilating effects.
View MoreShandong Topscience Biotech Co., Ltd.
Contact:0633-2619278
Address:No. 98 Lanshan West Road, Lanshan District, Rizhao, Shandong Province, P.R. of China
Wuhan Chemchemical Co., Ltd.(expird)
Contact:15973022782
Address:7-5-6218,Incubation Centre,Guandong Industry Park, East Lake High-Tech Development Zone,Wuhan City.
SHUNYUANSHENG BIO-PHARMTECH CO., LTD
website:https://www.whsysbio.com
Contact:--
Address:Building 13, Liandong U Valley-Wuhan Economic Innovation Valley, No. 259, Xingsan Road, Shamao Street, Hannan District, Wuhan City, Hubei Province
Hubei ShiNan Pharmaceutical Chemical co., Ltd.(expird)
Contact:+86-13554447107
Address:Wuhan HongShanOu wu no road 378 future residence building 1 unit 14 layer no. 1401 A
Shanghai Send Pharmaceutical Technology Co., Ltd.
website:http://www.shsendpharma.com
Contact:021-58088081, +8613585868794
Address::Room A601, Building 1,NO. 800 Qingdai Road Pudong District Shanghai,China
Doi:10.1021/ol005535b
(2000)Doi:10.1134/S1070363212100155
()Doi:10.1021/ja01566a053
(1957)Doi:10.1039/b711743d
(2007)Doi:10.1016/j.bmc.2012.01.033
(2012)Doi:10.1002/open.201900055
(2019)